Literature DB >> 7902654

Current situation of African trypanosomiasis.

F A Kuzoe1.   

Abstract

African trypanosomiasis (sleeping sickness) is fatal, if untreated, and occurs in 36 African countries, south of the Sahara, where some 50 million people are at risk of acquiring infection. In the absence of adequate control measures epidemics occur, which are costly and difficult to control. The history of sleeping sickness has been characterized by waves of epidemics, resurgences and outbreaks. Nevertheless, sleeping sickness has been brought practically under control in the early 1950s, in West and Central Africa, through systematic surveillance of the population at risk and in East Africa, mainly by vector control. Following the attainment of independence from colonial rule in subsequent years, failure by national health authorities to give due attention to sleeping sickness control, due to civil and political unrest, lack of adequate resources and competing national health priorities, has resulted in epidemics and the recrudescence of many old foci and the appearance of new ones. Thus, sleeping sickness is currently a major concern among many countries, particularly in East and Central Africa. During the past decade, progress has been achieved through research in the development of new tools for diagnosis, which are simple to use by national health personnel and for vector control, which can be used at the community level. Eflornithine, a new drug, has been registered for the treatment of gambiense sleeping sickness, and although it is expensive, it is relatively safe and provides an alternative therapy to the existing treatment, which may cause severe adverse effects. These tools have raised hopes for improved control, but their integration into health care systems, which could improve surveillance of the population at risk, has been slow. In view of the worsening economic situation of endemic countries, and the focus of attention and resources on the AIDS pandemic, prospects of any significant improvement in the sleeping sickness situation would largely depend on the successful mobilization of external resources.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902654     DOI: 10.1016/0001-706x(93)90089-t

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  30 in total

Review 1.  Human African trypanosomiasis of the CNS: current issues and challenges.

Authors:  Peter G E Kennedy
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 2.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

Review 3.  Transmission of tropical and geographically restricted infections during solid-organ transplantation.

Authors:  P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

4.  Synthetic nonamer peptides derived from insect defensin mediate the killing of African trypanosomes in axenic culture.

Authors:  Hiroshi Kitani; Jan Naessens; Masanori Kubo; Yoshio Nakamura; Fuad Iraqi; John Gibson; Minoru Yamakawa
Journal:  Parasitol Res       Date:  2009-03-24       Impact factor: 2.289

5.  Immunobiology of African trypanosomes: need of alternative interventions.

Authors:  Toya Nath Baral
Journal:  J Biomed Biotechnol       Date:  2010-02-23

6.  In vitro and in vivo activities of trybizine hydrochloride against various pathogenic trypanosome species.

Authors:  R Kaminsky; R Brun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  The development of drugs for treatment of sleeping sickness: a historical review.

Authors:  Dietmar Steverding
Journal:  Parasit Vectors       Date:  2010-03-10       Impact factor: 3.876

8.  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

Authors:  Stefan O Ochiana; Vidya Pandarinath; Zhouxi Wang; Rishika Kapoor; Mary Jo Ondrechen; Larry Ruben; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2012-07-31       Impact factor: 6.514

9.  Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.

Authors:  Ning Qu; Natalia A Ignatenko; Phillip Yamauchi; David E Stringer; Corey Levenson; Patrick Shannon; Scott Perrin; Eugene W Gerner
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

10.  Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib.

Authors:  Dietmar Steverding; Xia Wang
Journal:  Parasit Vectors       Date:  2009-07-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.